Matching the Bipolar Patient and the Mood Stabilizer

References

• Pies R: Have we undersold lithium for bipolar disorder? J Clin Psychopharmacol 2002; 22:445–449
   Google Scholar
• Goodwin FK, Ghaemi SN: The difficult-to-treat patient with bipolar disorder. In: Dc wan MJ, Pies RW, eds. The Difficult-to-Treat Psychiatric Patient. Washington, DC: American Psy-chiatric Press; 2001:7–39
   Google Scholar
• Akiskal HS: The prevalent clinical spectrum of bipolar disor-ders: Beyond DSM-IV. I Clin Psychopharmacol 1996; 16:4S–14S
   Google Scholar
• US Department of Health Education and Welfare: Medical Practice Project: A State of the Science Report for the Office of the Assistant Secretary for the US Department of Health Education and Welfare; 1979
   Google Scholar
• Goldberg JF, Keck PE: Summary of findings on the course and outcome of bipolar disorders. In: Goldberg IF, Harrow M, eds. Bipolar Disorders: Clinical Course and Outcome. Washington, DC: American Psychiatric Press; 1999:275–288
   Google Scholar
• Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM: The National Depressive and Manic-Depressive Asso-ciation (DMDA) survey of bipolar members. J Affect Disord 1994; 31:281–294
   PubMed Web of Science ®Google Scholar
• Ghaemi SN, Boiman EE, Goodwin FK: Diagnosing bipo-lar disorder and the effect of antidepressants: A naturalistic study. J Clin Psychiatry 2000; 61:804–808
   PubMed Web of Science ®Google Scholar
• Ernst CL, Goldberg JF: The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 2002; 63 (Suppl 4):42–55
   PubMed Web of Science ®Google Scholar
• Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP: The expert consensus guidelines series: Medication treatment of bipolar disorder 2000 (Special issue). Postgrad Med 2000; 1–104
   Google Scholar
• Suppes T, Swann AC, Dennehy EB, Habermacher ED, Mason M. Crismon ML, Toprac MG, Rush Al, Shon SP, Altshuler KZ: Texas Medication Algorithm Project: Development and feasibility testing of a treatment algorithm for patients with bipolar disorder. I Clin Psychiatry 2001; 62:439–447
   Google Scholar
• American Psychiatric Association: Practice guideline for the treatment of patients with bipolar disorder (Revision). Am J Psychiatry 2002; 159:1–50
   Web of Science ®Google Scholar
• Goodwin FK, Jamison KR: Manic-Depressive Illness. New York: Oxford University Press; 1990
   Google Scholar
• Boland RJ, Keller MB: Mixed-state bipolar disorders: Out-come data from the NIMH Collaborative Program on the Psychobiology of Depression. In: Goldberg JE Harrow NI, eds. Bipolar Disorders: Clinical Course and Outcome. Washington, DC: American Psychiatric Press; 1999:115–128
   Google Scholar
• Freeman TW, Clothier JL, Pazzaglia P. Lesem MD, Swann AC: A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992; 149:108–111
   Google Scholar
• Keck PE, Jr, Nabulsi AA, Taylor JL, Henke CJ, Chmiel JJ, Stanton SP, Bennett JA: A pharmacoeconomic model of di-valproex vs. lithium in the acute and prophylactic treatment of bipolar I disorder. J Clin Psychiatry 1996: 57:213–222
   Google Scholar
• Tondo L, Baldessarini RJ, Floris G: Long-term clinical effec-tiveness of lithium maintenance treatment in types I and 11 bipolar disorders. Br J Psychiatry Suppl 2001: 41:s184–s190
   Google Scholar
• Emrich HM: Studies with oxcarbazepine (Trileptal) in acute mania. In: Emrich HM, Schiwy W, Silverstone T, eds. Carba-mazepine and Oxcarbazepine in Psychiatry. London: Clinical Neuroscience Publishers; 1990:83–88
   Google Scholar
• Ketter TA, Post RM, Denicoff K: Carbamazepine. In: Good-nick PJ, ed. Mania: Clinical and Research Perspectives. Washington, DC: American Psychiatric Press; 1998:263–300
   Google Scholar
• Ketter TA, Calabrese JR: Stabilization of mood from below versus above baseline in bipolar disorder: A new nomencla-ture. I Clin Psychiatry 2002; 63:146–151
   PubMed Web of Science ®Google Scholar
• McElroy SL, Keck PE, Jr, Pope HG, Jr, Hudson JI: Valproate in the treatment of bipolar disorder: Literature review and clinical guidelines. J Clin Psychopharmacol 1992; 12:42S–52S
   Google Scholar
• Calabrese JR, Woyshville MJ, Kimmel SE, Rapport DJ: Pre-dictors of valproate response in bipolar rapid cycling. J Clin Psychopharmacol 1993; 13:280–283
   PubMed Web of Science ®Google Scholar
• Winsberg ME, DeGolia SG, Strong CM, Ketter TA: Dival-proex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 2001; 67:207–212
   PubMed Web of Science ®Google Scholar
• West SA, Keck PE, McElroy SL: Valproate. In: Goodnick P, ed. Mania: Clinical and Research Perspectives. Washington, DC: American Psychiatric Press; 1998:301–317
   Google Scholar
• Strakowski SM, McElroy SL, Keck PE: Clinical efficacy of valproate in bipolar illness: Comparisons and contrasts with lithium. In: Halbreich U, Montgomery SA, eds. Phar-macotherapy for Mood, Anxiety, and Cognitive Disorders. Washington, DC: American Psychiatric Press; 2000: 143–157
   Google Scholar
• Ghaemi SN, Goodwin FK: Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex vs. lithium in the setting of minimal antidepressant use. .1 Affect Disord 2001; 65:281–287
   PubMed Web of Science ®Google Scholar
• Post RM, Denicoff KD, Frye MA, Leverich GS, Cora-Locatelli G, Kimbrell TA: Long-term outcome of anticon-vulsants in affective disorders. In: Goldberg JF, Harrow M, eds. Bipolar Disorders: Clinical Course and Outcome. Wash-ington, DC: American Psychiatric Press; 1999:85–114
   Google Scholar
• Ketter TA, Wang PW: The emerging differential roles of GABAergic and antiglutamatergic agents in bipolar disor-ders. J Clin Psychiatry 2003; 64 (Suppl 3):15–20
   Google Scholar
• Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA. Cora-Locatelli G, Leverich GS, Post RM: A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20:607–614
   Google Scholar
• Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G: Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000; 2:249–255
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders-Text Revision, 4th edn. Wash-ington, DC: American Psychiatric Press; 2000
   Google Scholar
• American Psychiatric Association: Diagnostic and Statisti-cal Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Press; 1994
   Google Scholar
• Koukopoulos A, Sani G. Koukopoulos AE, Minnai GP, Gi-rardi P. Pani L, Albert MJ, Reginaldi D: Duration and stability of the rapid-cycling course: A long-term personal follow-up of 109 patients. J Affect Disord 2003; 73:75–85
   Google Scholar
• Dilsaver SC, Swann AC, Shoaib AM, Bowers TC: The manic syndrome: Factors which may predict a patient's response to lithium, carbamazepine and valproate. J Psychiatry Neurosci 1993; 18:61–66
   PubMedGoogle Scholar
• Okuma T: Effects of carbamazepine and lithium on affective disorders. Neuropsychobiology 1993; 27:138–145
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Fatemi SH, Kujawa M, Woyshville MJ: Predic-tors of response to mood stabilizers. J Clin Psychopharmacol 1996; 16:24S–3[S
   Google Scholar
• Bowden CL: Predictors of response to divalproex and lithium. J Clin Psychiatry 1995; 56 (Suppl 3):25–30
   PubMedGoogle Scholar
• Dunner DL: A two-illness model of bipolar disorder-By RT Joffe, LT Young, and GM MacQueen: A Commentary. Bipolar Disord 1999; 1:36–37
   Google Scholar
• Baldessarini RI, Tondo L, Floris G, Hennen J: Effects of rapid cycling on response to lithium maintenance treatment in 360 bipolar land II disorder patients. J Affect Disord 2000; 61:13–22
   PubMedGoogle Scholar
• Dunner DL: Rapid cycling bipolar affective disorder. In: Goldberg JF, Harrow M, eds. Bipolar Disorders: Clinical Course and Outcome. Washington, DC: American Psychi-atric Press; 1999:199–217
   Google Scholar
• Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, Kusumakar V, Ascher JA, Earl NL, Greene PL, Monaghan ET: A double-blind, placebo-controlled, prophy-laxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61:841–850
   PubMed Web of Science ®Google Scholar
• Tondo L, Hennen J, Baldessarini RJ: Rapid-cycling bipo-lar disorder: Effects of long-term treatments. Acta Psychiatr Scand 2003; 108:4–14
   PubMed Web of Science ®Google Scholar
• Grof P, Alda M, Grof E, Fox D, Cameron P: The challenge of predicting response to stabilising lithium treatment. The importance of patient selection. Br J Psychiatry Suppl 1993; 16–19
   Google Scholar
• MacQueen GM, Trevor YL, Marriott M, Robb J, Begin H, Joffe RT: Previous mood state predicts response and switch rates in patients with bipolar depression. Acta Psychiatr Scand 2002; 105:414–418
   PubMed Web of Science ®Google Scholar
• Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Mor-ris DD: Mania: Differential effects of previous depressive and manic episodes on response to treatment. Acta Psychiatr Scand 2000; 101:444 451
   Google Scholar
• Maj M, Pirozzi R, Kemali D: Long-term outcome of lithium prophylaxis in patients initially classified as complete respon-ders. Psychopharmacology (Berl) 1989; 98:535–538
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K, Lavelle J: Comparison of standard and low-serum levels of lithium for maintenance treatment of bipolar disor-der, N Engl J Med 1989; 321:1489–1493
   Google Scholar
• Goldberg JF, Harrow M, Grossman LS: Course and outcome in bipolar affective disorder: A longitudinal follow-up study. Am J Psychiatry 1995; 152:379–384
   PubMed Web of Science ®Google Scholar
• Coryell W, Leon AC, TUrvey C, Akiskal HS, Mueller T, Endicott J: The significance of psychotic features in manic episodes: A report from the NIMH collaborative study. .I Af-fect Disord 2001:67:79–88
   PubMed Web of Science ®Google Scholar
• Mendlewicz J, Souery D, Rivelli SK: Short-term and long-term treatment for bipolar patients: Beyond the guidelines. J Affect Disord 1999; 55:79–85
   Google Scholar
• Brambilla P. Barale F. Soares JC: Atypical antipsychotics and mood stabilization in bipolar disorder. Psychopharmacology (Berl) 2003; 166:315–332
   Google Scholar
• Vieta E, Goikolea JM, Corbella B, Benabarre A, Reinares M, Martinez G, Fernandez A. Colom F. Martinez-Aran A, Torrent C: Risperidone safety and efficacy in the treat-ment of bipolar and schizoaffective disorders: Results from a 6-month, multicenter, open study. J Clin Psychiatry 2001; 62:818–825
   Google Scholar
• Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chen-gappa KN, Daniel DG, Petty F, Centorrino F, Wang R. Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V: Olanzapine versus placebo in the treatment of acute ma-nia. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156:702–709
   Google Scholar
• Tohen M, Jacobs TG, Grundy SL. McElroy SL. Banov MC, Janicak PG, Sanger T. Risser R. Zhang F, Toma V, Francis J, Tollefson GD, Breier A: Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000; 57:841–849
   Google Scholar
• Zarate CA, Jr, Narendran R. Tohen M, Greaney IL Berman A, Pike S, Madrid A: Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychia-try 1998; 59:24–28
   Google Scholar
• Fein S, McGrath MG: Problems in diagnosing bipolar disor-der in catatonic patients. J Clin Psychiatry 1990; 51:203–205
   PubMed Web of Science ®Google Scholar
• Cassidy EM, O'Brien M, Osman MF, Finucane J, O'Keane V: Lethal catatonia responding to high-dose olanzapine therapy. J Psychopharmacol 2001; 15:302–304
   PubMedGoogle Scholar
• Devanand DP, Lisanby SH, Sackeim HA: Special somatic treatments. In: Dewan MJ, Pies RW, eds. The Difficult-to-Treat Psychiatric Patient. Washington, DC: American Psy-chiatric Press; 2001:359–392
   Google Scholar
• Salam SA, Pillai AK, Beresford TP: Lorazepam for psy-chogenic catatonia. Am J Psychiatry 1987; 144:1082–1083
   PubMed Web of Science ®Google Scholar
• Pariser SF: Women and mood disorders. Menarche to menopause. Ann Clin Psychiatry 1993; 5:249–254
   PubMedGoogle Scholar
• Viguera AC, Nonacs R, Cohen LS, Tondo L, Murray A, Baldessarini RI: Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000; 157:179–184
   PubMed Web of Science ®Google Scholar
• Burt VK, Hendrick VC: Postpartum psychiatric disorders. In: Concise Guide to Women's Mental Health. Washsington, DC: American Psychiatric Press; 1997:63–77
   Google Scholar
• Faedda GL, Tondo L, Teicher MH, Baldessarini RI, Gelbard HA, forts GF: Seasonal mood disorders. Patterns of seasonal recurrence in mania and depression. Arch Gen Psychiatry 1993; 50:17–23
   PubMed Web of Science ®Google Scholar
• Whitney DK, Sharma V, Kueneman K: Seasonality of manic depressive illness in Canada. J Affect Disord 1999; 55:99–105
   PubMed Web of Science ®Google Scholar
• Cusin C, Serretti A, Mandelli L, Lucca A, Smeraldi E: Sea-sonal variations of lithiurriplasma levels. Psychiatry Res 2002; 111:35–41
   PubMed Web of Science ®Google Scholar
• Praschak-Rieder N, Neumeister A, Hesselmann B, Willeit M, Barnas C, Kasper S: Suicidal tendencies as a complication of light therapy for seasonal affective disorder: A report of three cases. J Clin Psychiatry 1997; 58:389–392
   PubMed Web of Science ®Google Scholar
• Schou M: Suicidal behavior and prophylactic lithium treat-ment of major mood disorders: A review of reviews. Suicide Life Threat Behav 2000; 30:289–293
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ: Can lithium help to prevent suicide? Acta Psychiatr Scand 2001; 104:161–162
   Google Scholar
• Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AL Clinical outcome in a randomized 1-year trial of cloza-pine versus treatment as usual for patients with treatment-resistant illness and a history of mania. Am J Psychiatry 1999; 156:1164–1169
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Alphs L, Green Al, Altamura AC, Anand R. Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J. Krishnan R. Lindenmayer JP, Potkin S: Clozapine treatment for suicidality in schizophrenia: International Suicide Preven-tion Trial (InterSePT). Arch Gen Psychiatry 2003; 60:82–91
   Google Scholar
• Papatheodorou G, Kutcher SP: Divalproex sodium treatment in late adolescent and young adult acute mania. Psychophar-macol Bull 1993; 29:213–219
   PubMedGoogle Scholar
• Maj M, Arena F, Lovero N, Pirozzi R, Kemali D: Factors associated with response to lithium prophylaxis in DSM Ill major depression and bipolar disorder. Pharmacopsychiatry 1985; 18:309–313
   PubMed Web of Science ®Google Scholar
• Coryell W, Akiskal H, Leon AC, Turvey C, Solomon D. En-dicott J: Family history and symptom levels during treatment for bipolar I affective disorder. Biol Psychiatry 2000; 47:1034–1042
   Google Scholar
• Ananth J. Pecknold JC: Prediction of lithium response in af-fective disorders. J Clin Psychiatry 1978; 39:95–100
   PubMed Web of Science ®Google Scholar
• Grof P. Duffy A. Cavazzoni P, Grof E, Garnham J, Mac-Dougall M, O'Donovan C, Aida M: Is response to prophylac-tic lithium a familial trait? J Clin Psychiatry 2002; 63:942–947
   Google Scholar
• Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis IM, Rush AJ, Small JG: Ef-ficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271:918–924
   PubMed Web of Science ®Google Scholar
• Regier DA, Farmer ME, Rae DS. Locke BZ, Keith SJ, Judd LL, Goodwin FK: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemio-logic Catchment Area (ECA) Study. JAMA 1990; 264:2511–2518
   Google Scholar
• Black DW, Winokur G, Hulbert J, Nasrallah A: Predictors of immediate response in the treatment of mania: The impor-tance of comorbidity. Biol Psychiatry 1988; 24:191–198
   PubMed Web of Science ®Google Scholar
• Himmelhoch JM: The paradox of anxiety syndromes co-morbid with bipolar disorder. In: Goldberg JF, Harrow M, eds. Bipolar Disorders: Clinical Course and Outcome. Washington, DC: American Psychiatric Press; 1999:237–258
   Google Scholar
• Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L: A history of substance abuse complicates remission from acute mania in bipolar disorder. J Clin Psychiatry 1999; 60:733–740
   PubMed Web of Science ®Google Scholar
• Weiss RD, Greenfield SF, Najavits LM, Soto JA, Wyner D, To-hen M, Griffin ML: Medication compliance among patients with bipolar disorder and substance use disorder.1 Clin Psy-chiatry 1998; 59: 172–174
   Google Scholar
• Albanese MJ, Clodfelter RC, Jr, Khantzian EJ: Divalproex sodium in substance abusers with mood disorder. J Clin Psy-chiatry 2000; 61:916–921
   Google Scholar
• Brady KT, Dansky BS, Sonne SC, Saladin ME: Posttraumatic stress disorder and cocaine dependence. Order of onset. Am J Addict 1998; 7:128–135
   PubMed Web of Science ®Google Scholar
• Ballasiotes AA, Skaer TL: Use of lamotrigine in a patient with bipolar disorder and psychiatric comorbidity. Clin Ther 2000; 22:1146–1148
   Web of Science ®Google Scholar
• Woodman CL, Noyes R, Jr: Panic disorder: Treatment with valproate. J Clin Psychiatry 1994; 55:134–136
   Google Scholar
• Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzel-nick DJ, Weisler RH, Greist JH, Sutherland SM: Treatment of social phobia with gabapentin: A placebo-controlled study. J Clin Psychopharmacol 1999; 19:341–348
   PubMed Web of Science ®Google Scholar
• Wozniak J, Biederman J, Richards JA: Diagnostic and thera-peutic dilemmas in the management of pediatric-onset bipo-lar disorder. J Clin Psychiatry 2001; 62 (Suppl 14):10–15
   PubMed Web of Science ®Google Scholar
• Zamvil L, Cannon J: Polypharmacy in children and ado-lescents. In: Ghaemi SN, ed. Polypharmacy in Psychiatry. New York: Marcel Dekker; 2002
   Google Scholar
• Hennessey JV, Jackson [MD: The interface between thyroid hormones and psychiatry. Endocrinologist 1996; 6:214–223
   Google Scholar
• Pies RW: The diagnosis and treatment of subclinical hypothy-roid states in depressed patients. Gen Hosp Psychiatry 1997; 19:344–354
   Google Scholar
• Surks MI, Sievert R: Drugs and thyroid function. N Engl J Med 1995; 333:1688–1694
   PubMed Web of Science ®Google Scholar
• Schou M: Forty years of lithium treatment. Arch Gen Psychi-atry 1997; 54:9–13
   PubMed Web of Science ®Google Scholar
• Isojarvi JI, Tauboll E, Pakarinen AJ, van Parys J, Rattya J, Harbo HF, Dale PO, Fauser BC, Gjerstad L, Koivunen R. Knip M, Tapanainen JS: Altered ovarian function and car-diovascular risk factors in valproate-treated women. Am J Med 2001; 111:290–296
   Google Scholar
• Garland EJ, Behr R: Hormonal effects of valproic acid? J Am Acad Child Adolesc Psychiatry 1996; 35:1424–1425
   Google Scholar
• Rasgon NL, Altshuler LL, Gudeman D, Burt VIC. Tanavoli S. Hendrick V. Korenman S: Medication status and polycystic ovary syndrome in women with bipolar disorder: A prelimi-nary report." Clin Psychiatry 2000; 61:173–178
   Google Scholar
• Post RM: Transduction of psychosocial stress into the neuro-biology of recurrent affective disorder. Am J Psychiatry 1992; 149:999–1010
   PubMed Web of Science ®Google Scholar
• McElroy SL, Keck PE, Jr, Pope HG, Jr, Hudson JI: Valproate in psychiatric disorders: Literature review and clinical guide-lines.1 Clin Psychiatry 1989; 50 (Suppl):23–29
   Google Scholar
• Pope HG, Jr, McElroy SL, Satlin A, Hudson JI, Keck PE, Jr, Kalish R: Head injury, bipolar disorder, and response to valproate. Compr Psychiatry 1988; 29:34–38
   PubMed Web of Science ®Google Scholar
• McCoy L, Votolato NA, Schwarzkopf SB, Nasrallah HA: Clinical correlates of valproate augmentation in refrac-tory bipolar disorder. Ann Clin Psychiatry 1993; 5:29–33
   Google Scholar
• Evans DL, Byerly MJ, Greer RA: Secondary mania: Diagno-sis and treatment. J Clin Psychiatry 1995; 56 (Suppl 3):31–37
   PubMedGoogle Scholar
• Ghaemi SN, Ko TY: Polypharmacy of bipolar disorder. In: Ghaemi SN, ed. Polypharmacy in Psychiatry. New York: Marcel Dekker; 2002:35–77
   Google Scholar
• Venkataraman V. Shader RI, von Moltke LL, Greenblatt DJ: Drug interactions in psychopharmacology. In: Shader RI, ed. Manual of Psychiatric Therapeutics. Philadelphia: Lippincott, Williams & Wilkins; 2003:441–469
   Google Scholar
• Hachad H, Ragueneau-Majlessi I, Levy RH: New antiepilep-tic drugs: Review on drug interactions. Ther Drug Monit 2002; 24:91–103
   PubMed Web of Science ®Google Scholar
• Yuen AW, Land G. Weatherley BC, Peck AW: Sodium val-proate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33:511–513
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Sullivan JR, Bowden CL, Suppes T, Goldberg JF, Sachs GS, Shelton MD, Goodwin FK, Frye MA, Kusumakar V: Rash in multicenter trials of lamotrigine in mood disorders: Clinical relevance and management. J Clin Psychiatry 2002; 63:1012–1019
   PubMed Web of Science ®Google Scholar
• Finley PR, Warner MD, Peabody CA: Clinical relevance of drug interactions with lithium. Clin Pharmacokinet 1995; 29:172–191
   PubMed Web of Science ®Google Scholar
• Hopkins HS, Gelenberg AJ: Serum lithium levels and the outcome of maintenance therapy of bipolar disorder. Bipolar Disord 2000; 2:174–179
   PubMed Web of Science ®Google Scholar
• Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD: A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I de pression. Lamictal 602 Study Group. J Clin Psychiatry 1999; 60:79–88
   PubMed Web of Science ®Google Scholar
• Chengappa KN, Rathore D, Levine J, Atzert R, Solai L. Parepally H, Levin H. Moffa N, Delaney J, Brat IS: Thpi-ramate as add-on treatment for patients with bipolar mania. Bipolar Disord 1999; 1:42–53
   Google Scholar
• Chengappa KN, Gershon S. Levine J: The evolving role ol topiramate among other mood stabilizers in the management of bipolar disorder. Bipolar Disord 2001; 3:215–232
   PubMed Web of Science ®Google Scholar
• Ketter TA, Wang PW: Predictors of treatment response in bipolar disorders: Evidence from clinical and brain imaging studies. J Clin Psychiatry 2002; 63 (Suppl 3):21–25
   PubMed Web of Science ®Google Scholar